Tocilizumab COVID-19 Study Shows Bias Against Observational Studies, Harvard Prof Says
Executive Summary
Study showing Roche’s Actemra decreased mortality in COVID-19 patients in ICUs by almost 10% was initially rejected by journal editors and then ignored by guideline writers and regulators. FDA officials and industry reps discuss what needs to be done to advance use of real-world evidence from observational studies.
You may also be interested in...
More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?
The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.
Real-World Data Could Get Boost From Trial Replication Project
Effort to replicate clinical trial results with real-world data could eventually allow for increased use in drug development.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.